Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery

Annals of Thoracic Surgery

Volumn 77, Issue 2, 2004, Pages 496-499

  Levin, Ricardo L ^a,b   Degrange, Marcela A ^a   Bruno, Gustavo F ^a   Del Mazo, Carlos D ^a   Taborda, Daniel J ^a   Griotti, Jorge J ^a   Boullon, Fernando J ^a  

^a Navy Hospital   (Argentina)

^b Postoperatory Cardiovasc C   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; METHYLENE BLUE; NITRIC OXIDE;

ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; DRUG EFFECT; FEMALE; HEMODYNAMICS; HUMAN; HYPOTENSION; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SURGICAL MORTALITY; SURVIVAL RATE; SYSTEMIC VASCULAR RESISTANCE; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VASCULAR DISEASE; VASCULAR RESISTANCE; VASOPLEGIC SYNDROME;

EID: 0442292295     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)01510-8     Document Type: Article

References (23)

1. Raikar G.V., Hisamochi K., Raikar B.L. Nitric oxide inhibition attenuates systemic hypotension produced by protamine. Thorac Cardiovasc Surg. 111:1996;1240-1246.
2. Evora P.R.B. O impacto cientifico da descoberta do oxido nítrico como vasodilatador e antitrombotico endógeno. Arq Bras Cardiol. 61:1993;3-5.
3. Evora P.R.B., Ribeiro P.J.F., Andrade J.C.S. Methylene blue administration in SIRS after cardiac operations. Ann Thorac Surg. 63:1997;12-13.
4. Andrade J.C.S., Batista Filho M.L., Evora P.R.B., et al. Methylene blue administration in the treatment of the vasoplegic syndrome after cardiac surgery. Rev Bras Circ Cardiovasc. 11:1996;107-114.
5. Myles P.S., Leong C.K., Currey J. Endogenous nitric oxide and low systemic vascular resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 11:1997;571-574.
6. Gomez W.J., Carvalho A.C., Honorio Palma J., Concalvez I., Buffolo E. Vasoplegic syndrome a new dilemma . J Thorac Cardiovasc Surg. 107:1994;942-943.
7. Tsuneyoshi I., Kannmura Y., Yoshimura N., et al. Nitric oxide as mediator of reduced responsiveness of mesenteric arteries taken from patients with surgical shock septic. Crit Care Med. 24:1996;1083-1086.
8. Tsuneyoshi I., Yamada H., Kakihana Y., Nakamura M., Nakano Y., Boyle W.A. III. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med. 29:2001;487-493.
9. Evora P.B., Roselino C.H., Schiaveto P.M. Methylene blue in anaphylactic shock. Ann Emerg Med. 30:1997;2.
10. Levin R., Degrange M., Bilbao J., Macarone P., Martinez Traba M., Del Mazo C. Sindrome vasoplejico postoperatorio; reversión con azul de metileno. Rev Argent Cardiol. 68:2000;593-595.
11. Yiu P., Robin J., Pattison W. Reversal of refractory hypotension with single-dose methylene blue after coronary artery bypass surgery. J Thorac Cardiovasc Surg. 118:1999;195-196.
12. Evora P.R.B. Should methylene blue be the drug of choice to treat vasoplegias caused by cardiopulmonary bypass and anaphylactic shock? J Thorac Cardiovasc Surg. 119:2000;632-633.
13. Levin R.L., Degrange M.A., Bilbao J., et al. Sindrome vasoplejico en postoperatorio de cirugía cardíaca. Reducción de la mortalidad mediante el empleo de azul de metileno. Rev Argent Cardiol. 69:2001;524-529.
14. Bilbao J., Levin R.L., Degrange M.A., et al. Sindrome vasoplejico en recuperación 2. Rev Argent Cardiol. 67:(Suppl II):1999;48. (abstract).
15. Argenziano M., Chen J.M., Choudhri A.F., et al. Management of vasodilatory shock after cardiac surgery identification of predisposing factors and use of a novel pressor agent . J Thorac Surg. 116:1998;973-980.
16. Taylor K. SIRS the systemic inflammatory response syndrome after cardiac operations . Ann Thorac Surg. 61:1996;1607-1608.
17. Gomes W.J., Carvalho A.J., Palma J.H., et al. Vasoplegic syndrome after open heart surgery. J Cardiovasc Surg (Torino). 39:1998;619-623.
18. Christakis G.T., Fremes S.E., Koch J.P., et al. Determinants of low systemic vascular resistance during cardiopulmonary bypass. Ann Thorac Surg. 58:1994;1040-1049.
19. Cremer J., Martin M., Redl H., et al. Systemic inflammatory response syndrome aftercardiac operations. Ann Thorac Surg. 61:1996;1714-1720.
20. Argenziano M., Choudhri A.F., Mozami N., Levin H., Landry D.H., Oz M.C. A prospective randomized trial of arginine vasopressine in the treatment of vasodilatadory shock after left ventricular assist device placement. Circulation. 96:(Suppl 2):1997;II286-290.
21. Pagni S., Austin E. Use of intravenous methylene blue for the treatment of refractory hypotension after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 119:2000;1297-1298.
22. Kofidis T., Struber M., Wilhelmi M., et al. Reversal of severe vasoplegia with single-dose methylene blue after heart transplantation. J Thorac Cardiovasc Surg. 122:2001;823-824.
23. Gando S., Kameue T., Nanzaki S., Hayakawa T., Nakanishi Y. Participation of tissue factor and thrombin in posttraumatic systemic inflammatory syndrome. Crit Care Med. 25:1997;1789-1795.